Liver Disease News and Research

RSS

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.

Gene variant linked to liver cirrhosis in Caucasians

A new study by German researchers found that a variation in the PNPLA3 (adiponutrin) gene was associated with cirrhosis of the liver and elevated transaminase (liver enzyme) levels in alcoholic Caucasians. The risk of cirrhosis in alcoholics in the genetic high risk group might be as high as 25 to 50%. Full findings are published in the January 2011 issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

16 Dec 2010

Gene variation linked to liver cirrhosis in alcoholic caucasians

16 Dec 2010

Researchers introduce new class of drugs for HCV patients

To improve the care for individuals infected with the hepatitis C virus, a major health problem and a leading cause of chronic liver disease around the world, nearly 200 international hepatitis experts have taken an important step in escalating the introduction of a new class of targeted therapies for HCV – direct-acting antivirals.

15 Dec 2010

Celulas Genetica to submit international patent application for Rutherford Procedure

Emerging Healthcare Solutions, Inc. announced today that its newly acquired biotechnology division Celulas Genetica will submit an international patent application for the Rutherford Procedure, a revolutionary new stem-cell treatment for liver disease.

10 Dec 2010

Novel therapy against hepatitis C disease

University of Maryland School of Pharmacy researchers have developed a mathematical model for choosing an appropriate dosage of the hepatitis medications for individual patients. The work helps explain why African American patients tend to not respond as well to the drugs as other patients.

8 Dec 2010

Boceprevir drug may cure hepatitis C

The outlook for patients with hepatitis C continues to improve as results from a clinical trial led by a Saint Louis University researcher found that the drug boceprevir helped cure hard-to-treat patients. The findings were reported at the 61st annual meeting of the American Association for the Study of Liver Disease's earlier in November.

7 Dec 2010

Advent of HAART leads to decrease in mortality among people living with HIV/AIDS

During the decade since the advent of highly active antiretroviral therapy (HAART), or 1996-2006, mortality among people living with HIV/AIDS (PLWHA) sharply decreased in the United States. So, too, did the percentages of PLWHA deaths attributable to AIDS-defining illnesses, just as there was a marked increase in the percentage of deaths attributable to heart, kidney, and liver disease.

2 Dec 2010

EHSI completes Celulas Genetica acquisition

Emerging Healthcare Solutions, Inc. today announced its acquisition of Celulas Genetica, a biotechnology firm based in Panama.

2 Dec 2010

Penicillamine challenge ineffective for detecting Wilson's disease in asymptomatic children

An Italian research team confirmed that the scoring system for Wilson's disease (WD) provides good diagnostic accuracy with 93% positive and 92% negative predictive values, respectively in children with mild liver disease. In asymptomatic children, a urinary copper excretion above 40 μg/24 hours was suggestive of WD, however the penicillamine challenge test (PCT) did not provide an accurate diagnosis in this patient subset.

1 Dec 2010

IBD patients with hospital-acquired infections experience increased risk of inpatient mortality

Death and length of stay are increased among hospitalized inflammatory bowel disease (IBD) patients who develop hospital-acquired infections, according to a study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute.

1 Dec 2010

FDA approves Merit's phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere Microspheres

The Food and Drug Administration (FDA) has approved Merit Medical Systems, Inc.'s phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere™ Microspheres (hqTACE) for delivery of doxorubicin. The clinical trial will involve U.S. and international interventional radiologists who treat patients with localized, unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer.

29 Nov 2010

Selcia announces drug discovery collaboration agreement with Gilead Sciences

Selcia Limited, a leading contract research organisation, today announced a drug discovery collaboration agreement with Gilead Sciences, Inc. (Foster City, California).

29 Nov 2010

Most 'worried well' groups at risk of liver disease

Growing groups of the so-called "worried well" are putting their lives at risk by shunning visits to their GP over alcoholic health related matters, according to new evidence.

25 Nov 2010

Hepcidin hormone may be potential therapeutic tool for anemic blood disorders

A hormone made by the body may be a potential therapeutic tool for the treatment of two anemic blood disorders beta-thalassemia and hemochromatosis. The new research was led by scientists at Weill Cornell Medical College and published in the Journal of Clinical Investigation and the journal Blood.

24 Nov 2010

New IQQA Suite provides total solutions for liver cancer diagnosis, operative treatment management

EDDA Technology Introduces IQQA-Liver Suite To Provide Dedicated Total Solutions For Liver Cancer Diagnosis And Treatment Management

24 Nov 2010

Mother’s high-fat diet alters fetal genes that regulate circadian rhythm: Study

The link between sleeping and obesity is drawn tighter as a new research published online in the FASEB Journal study shows that what your mother ate when she was pregnant may make you obese or overweight by altering the function of genes (epigenetic changes) that regulate circadian rhythm.

23 Nov 2010

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

Childhood obesity linked to adult metabolic abnormalities and cardiovascular disease

Mounting evidence linking childhood obesity to an increasing risk of obesity, heart disease, type 2 diabetes, and other cardiovascular and metabolic disorders in adulthood is clearly presented in a comprehensive review article in the current issue of Childhood Obesity, published by Mary Ann Liebert, Inc. The article is available free online.

19 Nov 2010

Study finds Hispanic children are susceptible to develop fatty liver disease

Two studies from the Childhood Obesity Research Center at the Keck School of Medicine of the University of Southern California (USC) have found evidence that Hispanic children and adolescents are genetically predisposed to developing fatty liver disease a condition that can lead to cirrhosis, cardiovascular disease and diabetes.

18 Nov 2010

New cellular pathway could help develop therapeutic treatments for obesity-related disorders

Cardiac researchers at the University of Cincinnati (UC) have found a new cellular pathway that could help in developing therapeutic treatments for obesity-related disorders, like diabetes and heart disease.

17 Nov 2010